Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 14, 2023 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting

BOSTON, June 14, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
June 07, 2023 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Host Investor Call

BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
June 05, 2023 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
May 25, 2023 17:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression, with five confirmed partial responses (PRs) and three...
May 15, 2023 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Company to host Investor Update call on June 14, 2023 to review and discuss the clinical progress and associated data presented at ASCO BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma,...
May 09, 2023 16:35 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
May 08, 2023 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
April 25, 2023 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors

BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
April 12, 2023 08:00 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
March 21, 2023 16:10 ET | Source: Cue Biopharma, Inc.

Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

Received U.S. Food and Drug Administration (FDA) acceptance of Investigational New Drug (IND) application for CUE-102 in Wilms’ Tumor 1 (WT1)-expressing cancers and initiated dosing in a Phase 1 dose...